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Abstract 
Objective: To determine whether smoking status effects pain and functional outcomes in a chronic pain 
program. 
Methods: A retrospective cohort study of 178 patients treated at the Nebraska Medicine comprehensive 
Pain Management Program over a five year period was completed. Outcomes measures were the Visual 
Analog Scale Past Month Average Pain score (VAS-PMA), Multidimensional Pain Inventory pain and 
interference scales (MPI-P and MPI-I), and the Pain and Impairment Relationship Scale (PAIRS). Patients 
were categorized by smoking status into non-smoker or current smoker groups. Wilcoxon tests were used 
to compare the pre scores, post scores, and post-minus-pre scores between smoking status groups. 
Results: The pre-treatment VAS-PMA and MPI-P median scores were significantly higher in the current 
smoker group (81.5 and 5.0, respectively) compared to the non-smoker group (76.5 and 4.3, respectively), 
whereas post-treatment median scores did not differ. Furthermore, the current smoker group had a 
significantly greater decrease on the MPI-P from pre- to post-treatment (median=-2.0) than the non-
smoker group (median=-1.6). In addition, smokers had a significantly higher pre-treatment PAIRS score 
(73.5) than nonsmokers (70), whereas post-treatment scores did not differ. 
Conclusion: Smokers and non-smokers both benefit from the program, but smokers, who report greater 
initial pain and stronger beliefs about the association between pain and functional impairment, may 
benefit more than non-smokers. 
Keywords 
Chronic Pain Programs, Smoking, Chronic pain 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 
License. 
This original report is available in Graduate Medical Education Research Journal: https://digitalcommons.unmc.edu/
gmerj/vol1/iss1/4 
Dec. 2019  |  Vol. 1  |  Issue 1 Original Reports 12
Comprehensive Chronic Pain Treatment: Does Smoking Affect Outcomes?
Jamison Hofer1, David Cates2, Valerie K. Shostrom3, Brendan Thelen4, Kimberley Haynes-Henson5
1University of Nebraska Medical Center, Department of Neurology 
2University of Nebraska Medical Center, Department of Psychiatry
3University of Nebraska Medical Center, College of Public Health, Department of Biostatistics  
4Kaiser Permanente, Sacramento, CA
5University of Nebraska Medical Center, Department of Anesthesiology
https://doi.org/10.32873/unmc.dc.gmerj.1.1.004
Abstract
Introduction: Comprehensive pain programs 
are important for helping patients who have 
found little relief for their pain with other 
treatment modalities. It is important to know 
what factors affect the success of the program 
and who should be referred to the program. 
This study seeks to determine whether 
smoking status affects pain and functional 
outcomes in a chronic pain program.
Methods: A retrospective cohort study of 
178 patients treated at the Nebraska Medicine 
comprehensive Pain Management Program 
over a five-year period was completed. 
Outcome measures were the Visual Analog 
Scale Past Month Average Pain score (VAS-
PMA), Multidimensional Pain Inventory pain 
and interference scales (MPI-P and MPI-I), 
and the Pain and Impairment Relationship 
Scale (PAIRS). Patients were categorized by 
smoking status into non-smoker or current 
smoker groups. Wilcoxon tests were used 
to compare the pre-scores, post-scores, and 
post-minus-pre scores between smoking status 
groups.
Results: The pre-treatment VAS-PMA and 
MPI-P median scores were significantly 
higher in the current smoker group (81.5 and 
5.0, respectively) compared to the non-smoker 
group (76.5 and 4.3, respectively), whereas 
post-treatment median scores did not differ. 
Furthermore, the current smoker group had 
a significantly greater decrease on the MPI-P 
from pre- to post-treatment (median=-2.0) 
than the non-smoker group (median=-1.6). 
In addition, smokers had a significantly 
higher pre-treatment PAIRS score (73.5) than 
nonsmokers (70), whereas post-treatment 
scores did not differ.
Conclusion: Smokers and non-smokers 
both benefit from the program, but smokers, 
who report greater initial pain and stronger 
beliefs about the association between pain and 
functional impairment, may benefit more than 
non-smokers.
Introduction
Patients with chronic pain often fail to find 
relief with multiple types of medical and 
surgical interventions and may be referred to 
comprehensive pain programs (CPP). These 
intensive programs offer a multidisciplinary 
approach that enables patients to better 
manage their pain using psychological, 
behavioral, and physical therapy techniques. 
Treatment typically involves meeting 
individually and in groups with psychologists, 
physical therapists, nurses, and physicians 
to learn strategies to maximize function 
and better cope with pain. To date, there 
have been few studies of patient factors that 
correlate with CPP success.1,2 However, 
smoking and its relationship to chronic pain 
has long been studied, with smokers often 
reporting a greater number of painful sites and 
pain intensity compared to non-smokers.1,3 
It is not known whether smoking status is 
associated with outcomes in CPPs. One prior 
study evaluated the relationship between 
smoking status and outcomes among patients 
who completed a CPP, finding a negative 
association between smoking and employment 
status after the program.4 There is a need for 
more data regarding the impact of smoking 
on CPP outcomes. A retrospective cohort 
study was performed analyzing outcomes of 
the Nebraska Medicine comprehensive Pain 
Management Program over a five year period, 
to identify if smoking status correlated with 
treatment outcomes as measured by the Visual 
Analog Scale (VAS), Multidimensional Pain 
Inventory (MPI), and Pain and Impairment 
Relationship Scale (PAIRS).5,6,7
Methods
Measures: Visual Analog Scale (VAS). The 
VAS is a series of 10-centimeter lines with 
descriptive anchors at each end (“No pain” 
and “Pain at its worst”) on which patients 
are asked to mark an “X” to represent their 
average level of pain on a good day, bad day, 
today, and over the past month, respectively. 
The past month average pain level was 
identified, a priori, for use in the current 
study.6 
Multidimensional Pain Inventory (MPI). 
The MPI is a 61-item questionnaire with 13 
subscales assessing the psychosocial impact 
of chronic pain. Two subscales were identified 
a priori for use in this study, namely the 
“Pain” scale, to measure pain intensity and 
pain-related suffering, and the “Interference” 
scale to measure interference of pain in 
relationships and daily activities.7 
Pain and Impairment Relationship 
Scale (PAIRS). The PAIRS is a 15-item 
questionnaire measuring the extent to which 
patients believe their pain is associated with 
their functional status or impairment. Each 
item consists of a statement followed by a 
7-point Likert scale on which patients indicate
their level of agreement or disagreement with
the statement (e.g., “I have come to accept
that I am a disabled person due to my chronic
pain.”).5
Procedures: The Nebraska Medicine Pain 
Management Program is a multidisciplinary, 
four-week, day-long treatment program, 
designed to help individuals with chronic 
non-malignant pain. Services are provided 
in a multidisciplinary format by clinical 
psychologists, physical therapists, a nurse, 
and a pain physician. Assessment and 
treatment services are comprehensive 
and integrated. The primary purpose of 
the program is to help patients cope more 
effectively with pain-related problems and 
maximize their functioning. Specifically, 
treatment involves three components, which 
occur simultaneously: Physical therapy, 
psychological treatment, and medication 
program/nursing, with the latter involving a 
physician-monitored opioid tapering program 
for patients who enter the program on opiates. 
Admission criteria include pain that is chronic 
and non-malignant; desire for non-invasive 
pain treatment; stability of other medical 
problems; no psychiatric hospitalizations, 
suicide attempts, self-harm or harm to others 
in the last three months; involvement of a 
family member or significant other for a 
one-time meeting; willingness to complete 
an opiate medication taper with the goal 
of remaining off opiate pain medication 
in the long term; free of substance abuse 
(illicit drugs, alcohol, misuse of prescription 
medications); memory and concentration 
adequate to benefit from classroom lectures; 
5 minute walking tolerance; and ability 
to complete a floor to standing transfer 
independently. Patients may be referred by a 
primary care or specialty physician, or may 
be self-referred. Patients were not encouraged 
to quit smoking as part of the program, due 
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to the additional stress this would entail 
beyond that associated with the program 
itself. However, for those motivated to quit, 
the program helped develop a post- discharge 
plan for smoking cessation.
Pre- and post-intervention scores on the Visual 
Analog Scale past month average (VAS-
PMA), Multidimensional Pain Inventory 
pain and interference Scales (MPI-P, MPI-I), 
and Pain and Impairment Relationship Scale 
(PAIRS) were analyzed for patients over the 
age of 19-years old who participated in the 
Nebraska Medicine CPP from 2010 – 2015. 
Institutional Review Board (IRB) approval 
was obtained for the research. Smoking status 
was determined via chart review as part of 
a previous study.2 Former smokers were 
excluded as the duration of time since they 
had quit smoking was not established. 
PC SAS version 9.4 software was used for 
all analyses. Only subjects with complete 
data (pre- and post- values on all paired data) 
were included in the analyses. Demographic 
variables, including gender, race, and marital 
status, were examined for association with 
smoking status using Chi-Square tests or 
Fisher’s Exact Tests when cell counts were 
low. Outcome measures were tested for 
normality using the Wilks-Shapiro test. None 
of the outcomes passed the test of normality; 
thus, nonparametric Wilcoxon tests were 
used to compare the pre- scores, post- scores, 
and post-minus-pre scores between smoking 
status groups. The median and quartiles are 
presented. The outcome “program completed” 
was compared between smoking groups using 
a Fisher’s Exact Test. 
Results
Tables 1 and 2 show basic demographic data. 
A total of 178 patients were categorized by 
smoking status into non-smokers (N=120) 
and current smokers (N=58). The overall 
population was 70% female and 30% male, 
with 81% white and 19% non-white or 
unknown. Table 1 shows the mean age of 
the sample was 43.6 years, with a standard 
deviation of 12.88 years. Table 2 contains 
descriptive statistics and Chi-Square 
or Fisher’s Exact Test p-values for the 
comparison of smokers versus non-smokers 
on each of the demographic variables. None 
of the differences were statistically significant. 
Table 3 shows descriptive statistics (median 
and quartiles) and Wilcoxon p-values for 
the pre-treatment, post-treatment, and post-
minus-pre VAS-PMA scores for current 
smokers versus non-smokers. The pre-
treatment VAS-PMA median was significantly 
higher in the current smoker group (81.5) 
compared to the non-smoker group (76.5). 
However, the post-treatment VAS-PMA was 
not significantly different between current 
smokers (median=52) and non-smokers 
(median=53). The median difference (post – 
pre) was not statistically significant between 
the two groups.
Table 4 contains descriptive statistics (median 
and quartiles) and Wilcoxon p-values for 
the pre-treatment, post-treatment, and 
post-minus-pre MPI-P scores for current 
smokers versus non-smokers. Pre-treatment 
MPI-P scores were significantly higher in the 
current smoker group (median=5.0) versus 
the non-smoker group (median=4.3). The 
post-treatment median MPI-P score was 
not significantly different between smoking 
status groups. The current smoker group had 
a significantly greater decrease from pre- to 
post-treatment (median=-2.0) than the non-
smoker group (median=-1.6).
Table 5 shows descriptive statistics (median 
and quartiles) and Wilcoxon p-values for the 
pre-treatment, post-treatment, and post-minus-
pre MPI-I scores for current smokers versus 
non-smokers. None of the differences were 
statistically significant. 
Table 6 contains descriptive statistics (median 
and quartiles) and Wilcoxon p-values for 
the pre-treatment, post-treatment, and post-
minus-pre PAIRS scores for current smokers 
versus non-smokers. Pre-treatment PAIRS 
scores were significantly higher in the current 
smoker group (median=73.5) versus the non-
smoker group (median=70.0). There were no 
statistically significant differences in the post-
treatment PAIRS scores or the post-minus-pre 
PAIRS scores.
Table 7 shows descriptive statistics for the 
variable “program completed.” Two subjects 
from the non-smoker group had missing data 
for this variable and were not included in the 
summary or analysis. In total, 97% of current 
smokers completed the program compared 
to 99% of non-smokers. The result was not 
statistically significant.
Analyses were also performed to see if the 
changes from pre to post were significant 
within the smoking and non-smoking groups 
separately, using Wilcoxon signed rank test. 
The analyses within the two groups for each 
variable, including difference between VAS, 
Pain, Interference, and PAIRS, were all 
statistically significant in both smoking and 
non-smoking groups with a p-value less than 
0.0001. 
Discussion
Among the current sample of patients who 
completed a 4-week CPP, current smokers 
reported more pain at the start of the program 
compared to nonsmokers, as revealed by 
pre-treatment scores on both the VAS-PMA 
and the MPI-P. This finding is consistent with 
previous research reporting a greater number 
of painful sites and higher pain intensity 
among smokers compared to their non-smoker 
counterparts.1,3 In addition to reporting greater 
pain intensity prior to treatment, current 
smokers in this study also reported stronger 
beliefs about the association between their 
pain and functional impairment compared 
to non-smokers, as reflected in the PAIRS. 
At the end of treatment, however, there 
was no evidence for a significant difference 
between groups in reports of pain, nor in the 
association between pain and impairment. 
The findings suggest that the program reduced 
pain intensity, and the extent to which 
patients believed their pain was associated 
with functional status, to the same level for 
both current smokers and non-smokers. In 
connection with the significantly higher 
pre-treatment pain scores as well as greater 
post-minus-pre MPI-P scores among current 
smokers compared to non-smokers, the results 
suggest that not only do current smokers 
benefit from the CPP but they may receive 
greater benefit when compared with a non-
smoking cohort. 
Conclusions
The Nebraska Medicine Pain Management 
Program had a high completion rate from 
2010 to 2015. Smokers and non-smokers 
both appear to benefit from the program, and 
smokers, who report greater initial pain, may 
benefit more than non-smokers. Smokers 
are excluded from some pain treatment 
modalities; however, the data suggest that 
smokers should not be excluded from CPPs. 
Further studies should assess whether 
adding smoking cessation counseling to 
CPPs increases the magnitude of successful 
outcomes. 
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Table 1.
Demographics (Gender, Race, Smoking History, 
Marital Status, Age).
Frequency Percent
Gender   
Female 125 70.22
Male 53 29.78
Race   
Not White/Unknown 34 19.10
White 144 80.90
Smoking History   
Current Smoker 58 32.58
Non-Smoker 120 67.42
















Gender (female) 38 (66%) 87 (73%) 0.3396

























Pre VAS-PMA 81.5 (73, 92) 76.5 (66, 88) 0.0230
Post VAS-PMA 52 (23, 75) 53 (35, 68) 0.7812
Post—Pre VAS-PMA -27 (-51, -7) -23 (-39, -9) 0.4028
Table 4.







Pre MPI-P 5.0 (4.0, 5.3) 4.3 (4.0, 5.0) 0.0214
Post MPI-P 2.5 (1.7, 3.7) 2.7 (2.0, 3.7) 0.3886
Post—Pre MPI-P -2.0 (-3.0, -1.0) -1.6 (-2.3, -0.7) 0.0362
Table 5.







Pre MPI-I 4.95 (4.50, 5.50) 4.80 (4.15, 5.40) 0.1264
Post MPI-I 3.20 (1.80, 4.10) 3.20 (2.20, 4.10) 0.9122
Post—Pre MPI-I -1.90 (-2.60, -0.70) -1.30 (-2.30, -0.75) 0.2278
Table 6.







Pre PAIRS 73.5 (67.0, 84.0) 70.0 (63.0, 79.0) 0.0386
Post PAIRS 45.5 (34.0, 63.0) 46.0 (37.5, 55.5) 0.9629
Post—Pre PAIRS -26.0 (-40.0, -15.0) -23.0 (-35.0, -14.0) 0.2961
Table 7.







Program Completed 56 (97%) 117 (99%) 0.2529
